Securities code: 000756 securities abbreviation: Shandong Xinhua Pharmaceutical Company Limited(000756) Announcement No.: 2022-06 Shandong Xinhua Pharmaceutical Company Limited(000756)
Announcement on receiving the notice of China Securities Regulatory Commission on suspension of examination of administrative license application
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Shandong Xinhua Pharmaceutical Company Limited(000756) (hereinafter referred to as “the company”) intends to issue non-public shares to Hualu Investment Development Co., Ltd. The company submitted the application documents for non-public offering of shares to the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) on July 15, 2021, and received the acceptance form for administrative license application of the CSRC (acceptance No.: 211868) issued by the CSRC on July 19, 2021, On July 30, 2021, we received the notice on the first feedback on the examination of administrative licensing projects issued by the CSRC (No. 211868).
On January 26, 2022, the company received the notice on suspension of examination of administrative license application of CSRC (No. 211868) issued by CSRC, because in the process of examining the administrative license application documents of our company for non-public offering of shares, Xinyongzhong Certified Public Accountants (special general partnership), the non-public offering audit institution employed by our company, was filed for investigation by the CSRC. According to the relevant provisions of item (III) of paragraph 1, Article 22 of the provisions on the implementation procedures of administrative license of China Securities Regulatory Commission, the CSRC decided to suspend the examination of the application for administrative license.
The company will submit an application to the CSRC to resume the examination of the application documents for the non-public offering of A-Shares after meeting the conditions for resumption of the examination. The company’s non-public offering of shares still needs the approval of the CSRC. There is uncertainty about whether it can be approved and the time of final approval. The company will fulfill the obligation of information disclosure in time according to the progress of the matter. Please pay attention to the investment risk.
It is hereby announced.
Shandong Xinhua Pharmaceutical Company Limited(000756) January 26, 2022
